annual screening for advisory leads, (2) if loss of capture is detected, even though all cases were due to lead displacement, it will allow for better planning in cases where the lead is perforated through a chamber. As there is poor correlation for the rest of the indications it might be worth conducting larger review of practices to establish whether the yield from routine screening is useful. Our institution will review practices over last 5 years subsequent to this finding.

39 THE PREVALENCE OF SLEEP DISORDERED BREATHING IN ELDERLY PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION

William Eysenck*, Neil Sulke, Steve Furniss, Rick Veasey. *Cardiology Research Department, Eastbourne Hospital, East Sussex Healthcare NHS Trust*

10.1136/heartjnl-2017-311726.39

Introduction Epidemiological data have demonstrated an independent association between sleep-disordered breathing (SDB) and atrial fibrillation (AF). We have developed an efficient and reliable screening service investigating SDB in patients (pts)>65 years with persistent AF. Polysomnography (PSG) in a sleep laboratory (lab) is the gold standard diagnostic tool but expense and waiting lists for sleep centres have resulted in a search for alternative methods. The Watch PAT (WP) is

efficient and reliable with strong correlation to PSG, potentially negating the requirement for sleep lab investigation.

Methods 20 pts>65 years, mean age 71 (45% male), with persistent AF awaiting treatment were investigated for SDB with WP. Total device expenditure including pt and technician cost were compared with predictive cost of PSG and sleep lab studies.

Results See table 1.

According to the UK NICE definition 18/20 (90%) had evidence of SDB. 8/20 (40%) could be considered to have severe sleep apnoea. The mean REM sleep percentage was 20.4% and mean snoring intensity was 40.9 dB. WP cost was significantly less than predictive cost of PSG ($p<0.0001$). Conclusion: There is a high prevalence of SDB in older pts with AF and use of the WP as a screening option is feasible. The higher than average non-REM sleep and only mildly elevated snoring intensity implicates a central component in these pts related to cardiac co-morbidity. Further study is ongoing to assess AF therapy outcomes in such pts.

40 RIGHT VENTRICULAR HIGH SEPTAL PACING VS. RIGHT VENTRICULAR APICAL PACING FOLLOWING AV NODE ABLATION: 20 YEARS FOLLOW UP

William Eysenck*, Rick Veasey, Angela Gallagher, Fadi Jouhra, Nikhil Patel, Steve Furniss, Neil Sulke. *Cardiology Research Department, Eastbourne Hospital, East Sussex Healthcare NHS Trust*

10.1136/heartjnl-2017-311726.40

Introduction Right ventricular septal (RVS) pacing is often recommended as a more physiological alternative to right ventricular apical (RVA) pacing. Most comparisons between the two sites have had short follow up and few trials have assessed the different pacing sites following atrioventricular node (AVN) ablation. We analysed 200 consecutive patients (pts) aged 66–96 (51% male) who underwent implantation of a pacemaker prior to AVN ablation with either RVA- or RVS-pacing between 1996 to 2016.

Methods All hospital notes were retrieved and reviewed. Radiographic data for the site of V lead, all hospitalisations, change in echocardiography ejection fraction (EF), QRS width trend and lead parameters were collated. All pts additionally underwent dyssynchrony echocardiography.

Results See tables 1 and 2.

Conclusions (i) EF of less than 40%; (ii) prior diagnosis of IHD and (iii) dilated cardiomyopathy independently predict HF admission following AVN ablation. However, there was no decrease in EF and no difference in inter-ventricular or intra-ventricular dyssynchrony with either pacing site after up to 20 year follow up. There was a decreased mortality rate with RVA pacing following AVN ablation after longterm follow up. We now prophylactically use CRT pacing in all pts with EF 40% and known IHD. Their outcome is part of ongoing follow up.

Abstract 39 Table 1 Sleep Test results in pts with persistent AF >65 screened for sleep-disordered breathing

Variable Tested	Mean ($\pm$ SD)
Neck circumference (cm)	41.85 ($\pm$ 5.829)
BMI (kg/m ²)	30.8 ($\pm$ 7.077)
Epworth score	8.54 ($\pm$ 4.502)
Mean sleep time (hours)	6.9017 ($\pm$ 1.835)
%REM	19.824 ($\pm$ 8.84)
Respiratory Disturbance Index	27.90 ($\pm$ 18.39)
Apnoea-Hypopnoea Index (AHI)	24.11 ($\pm$ 19.9)
Oxygen Desaturation Index	17.427 ($\pm$ 17.77)
Mean Respiratory Event	171.89 ($\pm$ 114)
Resp Event (AHI)	146.17 ($\pm$ 121)
Desaturations	104.22 ($\pm$ 104.77)
Mean snoring intensity (dB)	40.9 ($\pm$ 2.4)
Mean Cost : WatchPAT	£25.95 ($\pm$ 4.8)*
Predictive Cost PSG	£301.45 ($\pm$ 78.4)

*Mean cost of WP is less than corresponding predictive cost of PSG ($P<0.0001$)

Abstract 40 Table 1 Baseline characteristics

Pacing site	RVS pacing	RVA pacing	P Values
N	77	123	
Age (mean $\pm$ SD)	83.1 ($\pm$ 9.8)	84.1 ($\pm$ 13.2)	ns
Sex, n (%)			
Male	34 (45%)	65 (53%)	ns
Female	42 (55%)	58 (47%)	ns
Underlying heart disease, n (%)			
No underlying heart disease	36 (47%)	53 (43%)	ns
Ischaemic heart disease	12 (16%)	25 (20%)	ns
Cardiomyopathy	18 (23%)	41 (33.3%)	ns
Valvular heart disease	27 (35%)	41 (33.3%)	ns
Baseline ejection fraction (%) (mean $\pm$ SD)	52.0 ($\pm$ 10.6)	48.4 ($\pm$ 13.8)	ns
Follow-up ejection fraction (%) (mean $\pm$ SD)	55 ($\pm$ 11.3)	53.1 ($\pm$ 8.5)	ns
Survival Time (Years) (mean $\pm$ SD)	10.5 ($\pm$ 1.1)	13.9 ($\pm$ 0.6)	0.00001
Survival Time (Years) (median $\pm$ SD)	8.8	16.7	0.00001

Abstract 40 Table 2 Patient characteristics with and without left ventricular decompensation

	Developed CHF	No development of CHF	P Values
n	29	171	ns
Age (mean $\pm$ SD)	79.4 ($\pm$ 7.9)	77.7 ($\pm$ 6.4)	0.8
Gender, n (%)			
Male	17 (59%)	80 (48%)	0.1
Female	12 (41%)	87 (52%)	
Disease			
IHD	19 (67%)	19 (11.5%)	0.0001
Dilated Cardiomyopathy	19 (67%)	36 (21.8%)	0.0001
Valvular heart disease	13 (44%)	55 (33%)	0.5
Ejection fraction (%) prior to AVN ablation	39.3%	52%	0.01
QRS duration (mean $\pm$ SD)			
At baseline:			ns
Following AVN ablation:			
0-40 months	154.6 ($\pm$ 11.4);	143.4 ($\pm$ 20.9);	ns
40-80 months	159.3 ($\pm$ 13.3);	163.0 ($\pm$ 49.6);	ns
80-120 months	164.3 ($\pm$ 12.6)	134.0 ($\pm$ 20.0)	ns